Two members of the research team demonstrating how the
rTMS coil is placed during use.
By:
Jasmine Rooke, Bruyère Health Research Institute
Pain and symptom management are quintessential parts of palliative care, but there is more to care than physical treatments. When it comes to palliative and end-of-life care, psychological and existential distress are common, but very real concerns for patients and their families.
Palliative researchers at Bruyère Health are looking at how existential distress can be addressed using new treatment protocols.
In a first-of-its-kind study, patients admitted to Bruyère Health's academic palliative care unit with advanced illness and experiencing existential distress responded positively to accelerated repetitive transcranial magnetic stimulation (rTMS) treatment. As a small, proof-of-concept study, researchers saw virtually every participant experience more than a 50 percent improvement in symptoms of depression, anxiety, or both two weeks post-treatment.
rTMS is a non-invasive brain stimulation technique that is already used for treating mood and anxiety disorders, including major depression and post-traumatic stress disorder, but this is the first time the technique has been studied in the treatment of existential distress in a palliative setting.
One of the challenges inherent to a palliative care setting is that many therapeutic options to treat depression and distress, including drugs and psychotherapy, require significant time to take effect – time that patients may not want to spend in treatment at their stage of illness, or time they do not have.
The benefits of the study's rTMS protocol meant using a new accelerated five-day therapeutic approach that gave participants an option for relief in a short time period.
Dr. James Downar, the lead author and Investigator with the Bruyère Health Research Institute and co-chair of the Pan-Canadian Palliative Care Research Collaborative, sees this research as an important step toward finding effective and rapid treatments that are scalable across settings to help one of the most challenging forms of suffering for people at end-of-life.
In addition to shortening the window between treatment and effect, the development of portable rTMS devices offers potential for scaling beyond a hospital setting. Given how many Canadians indicate their preference would be to spend their last days in their own home, testing portable devices could open the possibility of offering community-based care.
With preliminary success in the study, the research team is looking ahead to conduct a full randomized clinical trial with a greater number of patients to fully understand how effective accelerated rTMS can be in treating existential distress.